第一单位：
Department of Oncology, Juravinski Cancer Center, Hamilton, ON, Canada.
作者：
Hira,Mian [1]
;
Christine,Eisfeld [2]
;
Christopher P,Venner [3]
;
Esther,Masih-Khan [4]
;
Moustafa,Kardjadj [5]
;
Victor H,Jimenez-Zepeda [6]
;
Cyrus,Khandanpour [2]
;
Georg,Lenz [2]
;
Arleigh,McCurdy [7]
;
Michael,Sebag [8]
;
Kevin,Song [9]
;
Richard,LeBlanc [10]
;
Darrell,White [11]
;
Julie,Stakiw [12]
;
Anthony,Reiman [13]
;
Martha,Louzada [14]
;
Muhammad,Aslam [15]
;
Rami,Kotb [16]
;
Engin,Gul [5]
;
Donna,Reece [4]
作者单位：
Department of Oncology, Juravinski Cancer Center, Hamilton, ON, Canada.
[1]
Department of Medicine, University Hospital Münster, Münster, Germany.
[2]
Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
[3]
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.;Canadian Myeloma Research Group, Toronto, ON, Canada.
[4]
Canadian Myeloma Research Group, Toronto, ON, Canada.
[5]
Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.
[6]
Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada.
[7]
Department of Medicine, McGill University, Montreal, QC, Canada.
[8]
BC Cancer Agency, Vancouver General Hospital, Vancouver, BC, Canada.
[9]
Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, QC, Canada.
[10]
Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
[11]
Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK, Canada.
[12]
Department of Medicine, Saint John Regional Hospital, Saint John, NB, Canada.
[13]
Department of Haematology, London Regional Cancer Center, London, ON, Canada.
[14]
Department of Medical Oncology, Allan Blair Cancer Centre, Regina, SK, Canada.
[15]
Department of Medical Oncology & Hematology, Cancer Care Manitoba, Winnipeg, MB, Canada.
[16]
DOI
10.3389/fonc.2022.826342
PMID
35251992
发布时间
2022-05-02
换一批
